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IMMUNOLOGY

Inhaled GM-CSF in neonatal mice provides durable
protection against bacterial pneumonia
Elizabeth M. Todd, Rashmi Ramani, Taylor P. Szasz, S. Celeste Morley*

INTRODUCTION

Pneumonia causes considerable morbidity and mortality in premature infants and neonates (1, 2), yet remarkably little is known
about host susceptibility to, and the pathophysiology of, lower
respiratory tract infections in this age group. In particular, the
development of innate immunity in preterm infant lungs is poorly
understood. Given that alveolar macrophages (AMs) have unique
roles as first responders to pathogenic infection and in maintaining
the anti-inflammatory, homeostatic environment of the lungs conducive to appropriate lung development, understanding how the
appearance of AMs is affected by preterm birth is essential to
understanding how preterm infants may respond to pulmonary
pathogen challenge (2–7).
A major paradigm shift occurred when Schulz et al. (8) demonstrated that tissue-resident macrophages arise during embryogenesis
from yolk sac precursors and are not continuously rederived from
circulating peripheral blood monocytes. The recognition that each
tissue-resident macrophage lineage derives along a unique pathway,
following distinct development and tissue-specific cues and finishing
with specialized phenotypic markers and functions, revolutionized
basic immunologists’ understanding and appreciation for the complex
nature of the tissue-resident phagocytic system (9–19). AMs epitomize the highly specialized nature of tissue-resident macrophages,
as they express CD11c (not CD11b) and depend on the growth
factor granulocyte-macrophage colony-stimulating factor (GM-CSF)
and the transcription factor peroxisome proliferator–activated
receptor . They also arise during a temporally limited phase of
development, which in mice begins on embryonic day 16 and closes
on postnatal day 7 (PND7). They arise from monocyte precursor
cells that seed the lungs of mice during embryonic days 15 and 16,
coincident with the saccular phase of lung development (20). These
monocytes develop to the intermediary pre-AM in the days before
birth and then advance to fully mature AMs in mice by PND7 (9).
Pre-AMs and AMs are phenotypically distinguished by surface
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markers; pre-AMs express CD11c, while AMs express both CD11c
and SiglecF. The pre-AM, as a developmental intermediary, can only
be found in the lungs from late embryonic or early neonatal mice
(not adult). AM development during the perinatal period is driven
by a burst of GM-CSF production, which subsides after birth (14).
After the first week of life, no new precursor cells are generated, and
in the absence of overwhelming inflammation, AMs self-renew over
the lifetime of the host (9, 21).
In addition to serving as sentinel cells, engulfing pathogens, and
preventing subsequent lung infection (13, 22), AMs are functionally
distinct from interstitial lung macrophages in that AMs are programmed
to tilt toward an anti-inflammatory, prohealing phenotype. AMs
thus protect and preserve the delicate alveolar structure from
inflammatory insults. In human infants, AMs can arise post-natally
in the first 2 days (3, 4, 6, 23, 24); therefore, we posit that the exogenous
augmentation of AM development may represent a new avenue to
protect preterm infants from pulmonary disease. In our mouse
model featuring the partial disruption of AM development, mice
were rendered susceptible to pneumococcal challenge (22, 25).
Mice lacking the actin-bundling protein L-plastin (LPL−/− mice)
and CD11c.Cre+-LPLfl/fl mice exhibited cell intrinsic defects in AM
production secondary to the diminished migration of AM precursors
to, and retention within, the alveoli. LPL−/− and CD11c.Cre+-LPLfl/fl
mice also exhibited impaired pneumococcal clearance from the
lungs following intratracheal challenge, associated with increased
dissemination to the bloodstream and decreased survival (22, 25).
Because GM-CSF signaling is independent of LPL (22), we considered
these mice to represent an ideal model system to test the therapeutic
potential of GM-CSF delivery to neonates. We now show that the
intranasal administration of GM-CSF to neonatal mice in the first
week of life enhances AM development. We note that the systemic
administration of GM-CSF did not enhance AM maturation as did
direct airway administration, and therefore, these effects would not
have been apparent in prior clinical trials of GM-CSF in preterm
infants (26). Most notably, the augmented population of AMs
persists to adulthood, and animals treated in the neonatal period
are protected as adults from mortality during pneumococcal lung
infection.
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Pneumonia poses profound health threats to preterm infants. Alveolar macrophages (AMs) eliminate inhaled
pathogens while maintaining surfactant homeostasis. As AM development only occurs perinatally, therapies that
accelerate AM maturation in preterms may improve outcomes. We tested therapeutic rescue of AM development
in mice lacking the actin-bundling protein L-plastin (LPL), which exhibit impaired AM development and increased
susceptibility to pneumococcal lung infection. Airway administration of recombinant granulocyte-macrophage
colony-stimulating factor (GM-CSF) to LPL−/− neonates augmented AM production. Airway administration
distinguishes the delivery route from prior human infant trials. Adult LPL−/− animals that received neonatal
GM-CSF were protected from experimental pneumococcal challenge. No detrimental effects on surfactant metabolism
or alveolarization were observed. Airway recombinant GM-CSF administration thus shows therapeutic promise to
accelerate neonatal pulmonary immunity, protecting against bacterial pneumonia.
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RESULTS

Neonatal rGM-CSF administration protected adult LPL−/−
mice from infection
To determine whether enhanced neonatal AM development protected
mice from subsequent infection, adult LPL−/− mice that received
neonatal rGM-CSF were challenged intratracheally with pneumococcus
(Fig. 2A). We selected the same inoculum used in our prior studies,
in which about 10 to 20% of WT animals would be expected to
Todd et al., Sci. Adv. 2019; 5 : eaax3387
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Neonatal rGM-CSF administration enhances
AM and AM precursor proliferation
We next sought to define a mechanism by which exogenous rGM-CSF
therapy enhanced AM neonatal development. We have previously
shown that the migration of AM precursors into the alveoli is
impaired in the absence of LPL. While it is not obvious how rGM-CSF
could overcome this migration defect, we hypothesized that exogenous
rGM-CSF could increase the proliferation of precursor cells that do
successfully reach the alveoli in LPL−/− pups—in other words, acting
on cells “already there.” Furthermore, the contribution of proliferation
to the increase in lung-resident monocyte, pre-AM, and AM populations
during neonatal development has not been previously assessed. We
therefore quantified 5-bromo-2′-deoxyuridine (BrdU) incorporation
into monocytes, pre-AMs, and AMs in PND3 pups treated intranasally
with PBS or rGM-CSF (Fig. 3A). AMs and precursors were identified
using surface expression of CD11b, F4/80, CD11c, SiglecF, and
Ly6C as previously defined [Fig. 1B and (9)]. In untreated WT pups,
we noted proliferation in all three subpopulations, with substantial
BrdU incorporation into fetal monocytes and AMs; meanwhile,
BrdU incorporation into all three cell types was diminished in
LPL−/− pups (Fig. 3, A and B). Notably, neonatal rGM-CSF treatment
significantly increased pre-AM proliferation by threefold in LPL−/−
pups (Fig. 3B); thus, one mechanism by which rGM-CSF restores
2 of 9
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Neonatal administration of rGM-CSF enhances
AM population in LPL−/− mice
We have previously shown that LPL−/− mice exhibit defective AM
development due to the impaired migration of pre-AM precursors
into the alveolar space (22). Impaired migration results in reduced
numbers of mature AMs and subsequent susceptibility to pneumococcal lung infection. Notably, AM precursors in LPL−/− mice retain
responsiveness to the required growth factor GM-CSF (22). We
undertook the present study to determine whether perinatal AM
development could be augmented by the exogenous intranasal
administration of GM-CSF and provide durable protection against
pneumococcal lung infection.
To test whether the airway administration of GM-CSF would
augment AM maturation during the normal physiological window
of development, we intranasally administered recombinant GM-CSF
(rGM-CSF) to wild-type (WT) and LPL−/− mouse pups or phosphate-
buffered saline (PBS) to control mice on the day of birth (DOB),
PND1, and PND2 (Fig. 1A). Mice were euthanized on PND3, and
populations of fetal monocytes, pre-AMs, and AMs in whole-lung
homogenates were determined by flow cytometry (Fig. 1B) (9). As
previously observed (22), untreated LPL−/− pups showed no deficiencies in fetal monocyte or pre-AM populations compared to WT
pups but did exhibit a reduced percentage of mature AMs. The
administration of rGM-CSF to LPL−/− pups increased the proportion
of CD11c+ maturing cells (combined pre-AMs and AMs; Fig. 1C),
while these proportions were unchanged by rGM-CSF administration
to WT pups. Administering the same amount of rGM-CSF (20 ng)
to LPL−/− pups via subcutaneous injection (systemic administration)
on DOB, PND1, and PND2 did not enhance AM maturation, as
assessed on PND6 (fig. S1).
To determine whether neonatal rGM-CSF administration elicited
durable change in AM numbers, we analyzed the percentage and
numbers of AMs recovered from adult (defined as ≥8 week old)
animals that had received intranasally either PBS or rGM-CSF as
neonatal pups. As previously observed (22), untreated adult LPL−/−
mice exhibited reduced AMs compared with WT mice (Fig. 1,
D and E). However, LPL−/− mice that had received rGM-CSF as pups
harbored significantly higher numbers of AMs in bronchoalveolar
lavage (BAL) fluid (Fig. 1E), while similarly treated WT mice
demonstrated no alteration in AMs. Thus, exogenous rGM-CSF
enhanced AM production under conditions where maturation was
impaired but did not alter normal AM development.
GM-CSF has been considered pro-inflammatory in the lung (27),
and excess inflammation has been associated with the disruption of
alveolarization in neonatal mice (5). To test whether the exogenous
administration of rGM-CSF to neonatal pups interfered with alveolarization in the developing lungs, histological sections of WT and
LPL−/− pups (PND3) and adults that received either PBS or rGM-CSF
were examined by a veterinary pathologist. No disruption of alveolarization was observed (fig. S2).

succumb, while up to 70 to 80% of LPL−/− mice might succumb.
This sizable differential in susceptibility would provide the optimal
conditions for observing an effect of neonatal rGM-CSF therapy, if
any (22, 25). As anticipated, untreated LPL−/− mice were more
susceptible to pneumococcal pneumonia than were WT mice (Fig. 2B).
However, adult LPL−/− mice that had received neonatal rGM-CSF
therapy were significantly protected from mortality, while the already
low mortality in infected WT mice was unaltered by neonatal rGM-CSF
therapy (Fig. 2B). Quantitative blood cultures obtained 24 hours
after pneumococcal inoculation revealed that untreated LPL−/− mice
suffered from augmented dissemination (Fig. 2C), as reported
previously (25) and aligned with their increased mortality. The
neonatal rGM-CSF treatment of LPL−/− mice reduced pneumococcal
bloodstream dissemination in infected adults to match that in WT
animals, showing that the neonatal administration of inhaled rGM-CSF
provided sustained rescue of pulmonary host defense. An analysis
of peripheral blood 24 hours after infection revealed no significant
difference in the percentages of circulating neutrophils or monocytes
in infected WT or LPL−/− mice treated with neonatal PBS or rGMCSF. LPL−/− mice exhibit reduced B cell maturation (28), which was
expectedly unchanged by neonatal rGM-CSF intranasal administration (Fig. 2D). Thus, we did not find evidence that intranasal
neonatal rGM-CSF treatment altered systemic host immune responses
(Fig. 2D) while protecting against pulmonary infection (Fig. 2, B and C).
We also quantified AMs in the BAL of adult animals that survived
2 weeks after intratracheal pneumococcal inoculation. AM numbers
in control and rGM-CSF–treated WT animals were equivalent.
Untreated LPL−/− mice again exhibited reduced AM numbers compared
to WT animals, while rGM-CSF–treated LPL−/− mice harbored AM
numbers equivalent to those of WT animals (Fig. 2E). We did not
observe any changes in the proportions of other pulmonary innate
immune cell types [dendritic cells (DCs), eosinophils, neutrophils,
or monocytes] preceding infection (Fig. 2F). Protection from pneumococcal infection thus correlated specifically with increased AM
populations.
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Fig. 1. Administration of rGM-CSF increases AMs in LPL mice. (A) rGM-CSF (20 ng) in 6 l of PBS was administered via intranasal (i.n.) instillation to neonatal pups on
DOB, PND1, and PND2. Mice were evaluated at indicated times after rGM-CSF administration. (B) Representative flow cytometry of whole-lung homogenates from PND3
WT and LPL−/− pups treated intranasally with PBS or rGM-CSF. (C) Quantification of the distribution of monocytes, pre-AMs, AMs, and total CD11c+ (maturing) cells in PND3
WT and LPL−/− pups. (D) Representative flow cytometry from BAL fluid obtained from adult WT and LPL−/− mice that had received neonatal rGM-CSF therapy. (E) Percentage
and number of AMs recovered from BAL fluid from adult WT and LPL−/− mice that had received neonatal rGM-CSF treatment. (C and E) n of each group is provided below
x axes. Data were obtained from four independent cohorts of animals. P values are determined using the Mann-Whitney U test. Kruskal-Wallis test comparing four groups
revealed P = 0.0014 for AM % (top) and P = 0.015 for AM numbers (bottom). The “n” of AM numbers (bottom) in some groups is lower than AM % (top) because cell
numbers in one experiment were counted manually rather than by cytometer acquisition. Only cell counts obtained by the same method (cytometer acquisition) are included
in data shown here.
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Fig. 2. Adult LPL−/− mice that received neonatal rGM-CSF therapy are protected
from pneumococcal infection. (A) Experimental design: Neonatal WT and LPL−/−
pups were intranasally given 20 ng of rGM-CSF or PBS (control) on DOB, PND1, and
PND2. After reaching adulthood, mice were challenged intratracheally (i.t.) with
pneumococcus. (B) Adult WT (gray) or LPL−/− (black) mice that had received neonatal
rGM-CSF therapy (open symbols) or PBS (control; closed symbols) were infected
intratracheally with pneumococcus and monitored for survival. Survival curves show
data combined from three independent experiments (WT + PBS, n = 19; WT + rGM-CSF,
n = 7; LPL−/− + PBS, n = 11; LPL−/− + rGM-CSF, n = 16) and were compared using
Mantel-Cox log-rank test. (C) Quantitative blood culture obtained from adult mice
24 hours after intratracheal instillation of pneumococci. Comparison of all groups by
one-way analysis of variance (ANOVA) (Kruskal-Wallis test), P = 0.0007. (D) Distribution
of neutrophils [polymorphonuclear leukocytes (PMNs)], monocytes, and B cells in
the peripheral blood of WT and LPL−/− mice challenged with pneumococcus. Mice
had received neonatal rGM-CSF therapy (GM) or PBS (P; control). (E) Number of
AMs recovered from BAL fluid of WT or LPL−/− adult mice that survived 2 weeks
after intratracheal pneumococcal infection. Grossly bloody BAL fluids were excluded from analysis (clotted). (F) Distribution of DCs, eosinophils, neutrophils
(PMNs), and monocytes in whole-lung homogenates from uninfected adult WT
and LPL−/− mice that had received neonatal rGM-CSF therapy or PBS (control).
Percentages of total CD45+ cells are given. (C to F) Data are combined from three
(C to E) or two (F) independent experiments. n of each group is given below
x axes. P values of comparisons between two groups are determined using the
Mann-Whitney U test.
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Neonatal rGM-CSF improves surfactant homeostasis
in LPL−/− mice
In addition to their critical role in host defense, AMs are essential to
surfactant metabolism. Surfactant is produced by alveolar epithelial
type II cells but taken up and catabolized in part by AMs, a process
stimulated by GM-CSF. Animals deficient in GM-CSF or the GM-CSF
receptor suffer from primary alveolar proteinosis, a progressive
and ultimately fatal accumulation of surfactant protein in the alveoli
(30–32). Although LPL−/− animals have not exhibited overt evidence
of progressive lung disease (22, 25), we have not previously formally
assessed surfactant protein in these mice. In addition, we wished to
determine whether neonatal rGM-CSF treatment would alter surfactant
catabolism in WT or LPL−/− mice. We therefore quantified surfactant
protein D (SP-D) and SP-A in WT and LPL−/− mice that had received
intranasally either PBS or rGM-CSF as pups (Fig. 4). In PND3 and
adult LPL−/− mice, the amount of SP-D per milligram of lung tissue
was increased in LPL−/− whole-lung homogenates compared to
untreated WT mice (Fig. 4A). Neonatal rGM-CSF therapy in LPL−/−
mice partially ameliorated the increase in SP-D by PND3 and
normalized SP-D concentrations by adulthood while not altering SP-D
levels in WT mice (Fig. 4A). SP-A concentrations were not altered
in the lungs of adult untreated LPL−/− mice and were not affected by
neonatal rGM-CSF therapy (Fig. 4B). An analysis of SP-D and SP-A
protein amounts compared to total lung protein revealed similar
trends (fig. S3). Therefore, neonatal rGM-CSF therapy did not alter
surfactant metabolism in WT mice but ameliorated defects in
LPL−/− mice associated with reduced AM production.
DISCUSSION

Here, we used a preclinical model of impaired AM development
to show that GM-CSF, a readily available, U.S. Food and Drug
Administration–approved therapy, can be administered safely to
the airways of newborn mice to accelerate AM maturation (Fig. 1)
and protect otherwise susceptible animals from bacterial pneumonia
(Fig. 2). One mechanism by which rGM-CSF rescues AM development
in LPL−/− mice is by significantly increasing pre-AM proliferation
(Fig. 3B) without affecting levels of TGF- or disrupting alveolarization or normal surfactant homeostasis (Fig. 4 and fig. S2). We
propose that the translation of neonatal GM-CSF therapy to human
infants could have a direct impact on improving outcomes of respiratory
disease in preterm neonates, a benefit that would not have been
apparent in prior studies that either subcutaneously or intravenously
4 of 9
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B
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mature AM numbers in LPL−/− mice is by enhancing the proliferation
of precursors that do succeed in reaching the alveolar space. Intranasal
rGM-CSF therapy had no effect on the proliferation of pre-AMs
or AMs in WT mice, again indicating that rGM-CSF therapy exerts
little, if any, effect on AM development that is proceeding normally
(Fig. 3B).
Recently, the autocrine production of transforming growth
factor– (TGF-) has been shown to be essential for AM development
and maintenance (29). We had not previously evaluated whether
TGF- production by AMs was altered by LPL deficiency. Furthermore,
if TGF- were dependent on LPL for generation, then a second
mechanism of AM rescue by rGM-CSF could be by augmenting
TGF- production. Refuting this possibility, we found no difference
in the whole-lung TGF- concentration in PND3 WT or LPL−/−
pups that had received PBS or rGM-CSF (Fig. 3C).
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administered systemic GM-CSF (26, 33). Our work shows that
the route and timing of GM-CSF administration—directly to the
airways, in the first 24 hours of life, to mimic the physiological
burst of GM-CSF production that naturally occurs (9)—could
exert effects very different from those previously observed when
GM-CSF was administered systemically and, later, postnatally.
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In addition, the present studies expand on our prior work revealing that LPL is an essential regulator of AM development
(22, 25); we now show that beyond supporting the migration
and adhesion of AMs and AM precursors into the alveoli (22),
LPL also facilitates the proliferation of AM precursors and developing
AMs (Fig. 3, A and B).
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CD16+ monocyte-macrophages and a decrease in the anticipated
mature, anti-inflammatory CD14+/CD36+ macrophages compared
to term infants. Furthermore, preterm infants that developed CLD
had significantly fewer mature anti-inflammatory CD14+/CD36+
macrophages (AMs) recovered from BAL fluid than did preterm
infants who did not develop CLD. Results from this study thus
correlate with mouse ontogeny models, in that a higher proportion
of immature (monocytic) cells is observed in preterm infants, and
suggest that this perturbation is associated with CLD (6).
Our data support the concept that the augmentation of AM
number and function, if perturbed in preterm infants, could confer
translational benefit to the preterm lung, both by protecting against
pulmonary infection (a common complication of prematurity) and
by promoting surfactant function and metabolism [as reduced AM
number impairs surfactant catabolism (36–38)]. In our mouse model
of deficient AM maturation, intranasal rGM-CSF restored AM numbers
and provided durable protection against pneumococcal challenge.
Similarly, in preterm rabbits, reduced AM number correlated with
increased susceptibility to group B streptococcal (GBS) lung infection
(4). Specifically, preterm rabbits harbored barely detectable AMs and
permitted the proliferation of GBS in the lungs, while term rabbits
had 17-fold higher numbers of AMs than preterms and easily cleared
a similar pulmonary GBS challenge (4). We also show an increase in
SP-D concentrations in LPL−/− neonatal pups (Fig. 4A), consistent
with reduced surfactant catabolism that would be anticipated with
diminished numbers of AMs [Fig. 1B and (22)]. Exogenous neonatal
rGM-CSF therapy reduced SP-D concentrations in PND3 LPL−/− pup
lungs concordant with the acceleration in AM maturation, suggesting
that the airway administration of GM-CSF to augment AM maturation
may promote surfactant homeostasis in preterm neonates.
Our data show that administering three doses of intranasal GMCSF to neonatal mice is feasible and was effective in promoting AM
maturation and pneumococcal clearance. The airway administration
of GM-CSF has not been previously studied in clinical trials of
human infants (26). One major clinical trial of GM-CSF administered
subcutaneous (systemic) GM-CSF to preterm infants within 72 hours
of birth, with a primary end point of sepsis-free survival at 14 days
of life and with a goal of increasing peripheral neutrophil counts.
No survival benefit of systemic GM-CSF was observed in this study
nor were any differences in oxygen requirements observed at 28 days
from enrollment (26). Follow-up evaluations of 2- and 5-year outcomes
revealed no differences in neurodevelopmental, growth, or infectious
outcomes with systemic GM-CSF administration (39, 40). We found
that the subcutaneous administration of GM-CSF did not increase
AM maturation as did direct airway administration (fig. S1). We
propose that direct airway administration results in higher alveolar
concentrations of rGM-CSF than does systemic injection, as systemic
injection would distribute rGM-CSF throughout all tissues, while
direct airway administration would provide a high alveolar concentration
before systemic absorption. Further pharmacokinetic studies could
define optimal dosing and timing of neonatal rGM-CSF to modify
AM development. A meta-analysis revealed a higher response rate
and greater improvements in PaO2 in subjects with autoimmune
pulmonary alveolar proteinosis treated with inhaled GM-CSF than
with subcutaneous GM-CSF (41). Inhaled GM-CSF has recently
been used to successfully treat Mycobacterium abscessus infections
in two patients with cystic fibrosis (42). We further note that we did
not find any evidence of adverse effects of neonatal rGM-CSF airway
administration to WT animals, in which AM maturation would be
6 of 9

Downloaded from http://advances.sciencemag.org/ on September 6, 2019

The observation that tissue-resident, long-lived macrophages arise
during prenatal development and then self-renew (8) overturned
the long-standing presumption that tissue-resident macrophages
are continually repopulated from circulating blood monocytes.
This finding prompted new work demonstrating the different
ontogeny and function of varied macrophage lineages (9, 11, 14–18, 21).
AMs represent a unique phagocytic lineage with a limited temporal
window for development (9), occurring in the perinatal period and
driven by a “burst” of GM-CSF occurring shortly after birth. The
maturation pathway from fetal liver monocyte to mature AM has
been well documented in mice (9, 14), and several key regulators
have been identified (29). Translation to humans, which requires
mapping of ontology and functional phenotypes of the multiple
interstitial and AMs in mice to corresponding lineages in humans,
will inform the role of each lineage in both lung infection and chronic
lung disease (CLD) in preterm infants. One major obstacle to
clinical translation has recently been overcome, as markers for clear
differentiation of human AMs from interstitial lung macrophages have recently been defined (24, 33). The recent characterization of distinct lineages (34, 35) now enables the re-evaluation of
prior links between CLD outcome and lung macrophages; for
instance, the macrophages studied in a landmark paper examining
alveolarization inhibition by macrophage-specific pro-inflammatory
signaling (5) were, in retrospect, likely fetal interstitial lung macrophages rather than AMs. The pathogenesis of CLD (including inhibition of airway maturation) might be greatly clarified by additional
studies leveraging new knowledge of macrophage lineages and AM
development.
Existing clinical data, examined in light of the new murine paradigm, support the consideration of AM maturation as a therapeutic
target. First, a similar monocyte-to-AM maturation may occur in
human infants (3, 6). While preterm lungs have been shown to bear
monocytes (6), very few, if any, mature AMs are present in the lungs
of stillborn infants (3, 24), strongly suggesting that AMs are not
present in the lungs of infants in utero. In a cohort of live-born
infants who died in the early neonatal period, AMs were present
in 33 of 46 (72%) infants who died before 48 hours of age but were
apparent in the lungs of 50 of 54 (93%) infants who survived longer
than 48 hours (3). Thus, the emergence of AMs in the lungs of
neonates correlated with time since birth, consistent with the murine
model in which AM precursors differentiate to mature AM shortly
after birth.
Moreover, the developmentally regulated increase of GM-CSF
noted in newborn mice has also been observed in humans (23). An
analysis of GM-CSF concentrations in amniotic fluid revealed gradually
increasing GM-CSF concentrations, beginning at 28 weeks of gestation
(23). After birth, tracheal aspirates demonstrated a sharp and significant
increase in GM-CSF concentrations in samples between 12 and
48 hours of age, after which concentrations did not change appreciably
(23). This study provides evidence that GM-CSF may also increase
at the time of birth in human infants, concurrently with the appearance
of mature AMs.
Because AMs are phenotypically and functionally distinct from
the interstitial macrophage lineages, delayed or disturbed AM
maturation in preterm and term neonates could be pathophysiologically
linked to either impaired immunity or increased pro-inflammatory
signaling associated with bronchopulmonary dysplasia or CLD. For
instance, the analysis of BAL fluid from preterm infants revealed
a significant increase in nonclassical, pro-inflammatory CD14+/

SCIENCE ADVANCES | RESEARCH ARTICLE

MATERIALS AND METHODS

Study design
Research objective
The primary objective of this research was to test the hypothesis that
administering rGM-CSF to neonatal LPL−/− pups (in the temporal
window of AM development) would protect LPL−/− mice during
subsequent bacterial lung infection. This objective was defined
before initiation of the experiments and data analysis.
Experimental design
The experimental design was a controlled laboratory experiment
using genetically modified mice.
Randomization
Pups within each litter of mice were randomly assigned to receive
intranasal rGM-CSF or PBS (control). In one set of experiments,
pups within litters were randomized to receive subcutaneous rGMCSF or PBS (control).
Todd et al., Sci. Adv. 2019; 5 : eaax3387
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Blinding
Histology sections were read by a veterinary pathologist who was
not associated with the study outcomes and was blinded to mouse
genotype and treatment group (slides were provided with coded
labels). Because of the technical challenges associated with working
with timed pregnancies and neonatal pups, and the necessity of
ensuring that pups receiving PBS could be consistently distinguished
from the pups receiving rGM-CSF (pups were marked with permanent
ink, but this would wear off if not reapplied), most of the studies
could not be blinded. However, the outcomes are all objectively
quantifiable [flow cytometry, colony forming units (CFU), etc.].
Mice
LPL−/− mice fully back-crossed to the C57BL/6 background have
been described (22, 25). WT and LPL−/− mice were bred and cohoused
in the same specific pathogen–free barrier animal facility. Human
rGM-CSF (20 ng in 6 l of PBS per inoculation) was administered
intranasally to pups in all experiments except for the data presented
in fig. S1. In fig. S1, some neonatal pups received 20 ng of rGM-CSF
in 10 l of PBS via subcutaneous injection. Litters of WT and LPL−/−
pups were divided such that approximately half received PBS and
half received rGM-CSF and such that littermate controls were used
to discern the effects of rGM-CSF. Mice matched for sex and age
were used in all experiments, which were conducted in accord
ance with a protocol approved by the Institutional Animal Care
and Use Committee at Washington University School of Medicine
(WUSM).
Cell isolation and media
BAL was performed as described (25), and cells were quantified by
flow cytometry (22). Lungs were homogenized using collagenase D
(2.5 mg/ml) in Hanks’ balanced salt solution and 3% fetal calf serum
(22).
Flow cytometry
Commercial antibodies to the indicated murine antigens were used:
CD11c-phycoerythrin (PE)/Cy7, CD11c-allophycocyanin (APC)
(N418), CD11c-APCCy7 (N418), CD64-PE (X54-5/7.1), F4/80-PerCP/
Cy5.5, F4/80-APC (BM8), I-Ak-PE (10-3.6), Ly-6C-PacBlue (HK1.4),
Ly-6C-BV510 (HK1.4), CD45-PacBlue (30-F11), CD45-BV785 (30-F11),
and Ly-6G-PacBlue (1A8) (all from BioLegend San Diego, CA);
CD11b-fluorescein isothiocyanate (M1/70), CD11b-PeCy7 (M1/70),
and CD11c-PE (N418) (all from eBioscience, San Diego, CA); CD45BV510 (104), SiglecF-PE, SiglecF–Alexa Fluor 647, SiglecF-APC700,
and (E50-2440) Ly6G-BUV395 (1A8) (all from BD Biosciences, San
Jose, CA); and MerTK-PE/Cy7 (DS5MMER) (from Invitrogen,
Carlsbad, CA). BrdU labeling was performed using the BrdU-APC
labeling Kit (BD Biosciences) according to the manufacturer’s
protocol. Cells were acquired either on the BD Biosciences LSRFortessa
or with a BD FACScan flow cytometer with DxP multicolor upgrades
by Cytek Development Inc. (Woodland Park, NJ) and then analyzed
using FlowJo software (FlowJo LLC, Ashland, OR). Samples were
preincubated with Fc-block [Hybridoma 2.4G2, American Type
Culture Collection (ATCC)].
Infection
Streptococcus pneumoniae [ATCC 6303, serotype 3; 5 × 104 CFU
per animal in 20 l of Dulbecco’s PBS) was instilled intratracheally as
before (22, 25). Blood was obtained for quantitative culture 24 hours
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expected to be proceeding normally, as assessed by alveolarization,
surfactant protein concentrations, and infectious susceptibility. We
therefore suggest that revisiting GM-CSF therapy in neonates via
this alternate route of administration would be warranted.
Furthermore, administering rGM-CSF to neonates with perturbed
AM development produced a longer-lasting effect (8 to 12 weeks)
than prior techniques using GM-CSF to protect against lung infections
(43). For instance, adenoviral-mediated expression continuously
delivered GM-CSF to the airway and protected mice from pneumococcal
pneumonia 14 days later, but the effect of GM-CSF on leukocyte
recruitment waned after 28 days of administration (43). The airway
administration of GM-CSF also improved clearance of pneumococcus
when given to adult mice from 12 hours before 6 hours after infection,
but clinical translation of this application was limited by the narrow
window of time for effective GM-CSF administration in relation to
pneumococcal infection (43). The airway overexpression of GM-CSF
driven by a surfactant promoter was also protective in a model of
influenza infection, as was the administration of GM-CSF 1 week
before infection (44). However, the sustained expression of GMCSF by either adenoviral or transgenic expression is not clinically
translatable, and the effect of GM-CSF administered to adults was
not durable. Our approach of administering GM-CSF during the
neonatal window of AM development is therefore unique and
clinically adaptable. We note that we did not challenge WT mice
with a pneumococcal inoculum anticipated to induce notable
mortality, as our intention was to test whether neonatal rGM-CSF
therapy of LPL−/− mice rescued susceptibility (Fig. 2A). While we
can conclude that neonatal rGM-CSF therapy did not increase
susceptibility of WT animals to lung pneumococcal infection, further
studies at higher inocula are required to test whether neonatal
rGM-CSF therapy also boosts antipneumococcal immunity in WT
mice. Last, also supporting the translatability of this approach, GMCSF has been administered to the airways of a small cohort of adults
with refractory acute respiratory distress syndrome, providing
benefit in oxygenation and lung compliance compared with control
patients (45). The successful use of rGM-CSF to provide sustained
protection against bacterial pneumonia in susceptible neonatal
mice, without perturbing airway immunity and lung development
in the normal host, illuminates how the airway administration of
GM-CSF might be used in preterm infants to improve clinical
outcomes in this highly vulnerable patient population.
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after inoculation. Mice were monitored at least twice daily using a
“humane end points” scoring system that included daily weight and
temperature monitoring and observation of animals’ grooming,
activity, behavior, and respirations. Animals that lost >20% of starting
weight or that scored >5 on the clinical observation score were
euthanized.
Tissues were harvested for either flow cytometry or for histology.
Histological specimens were preserved in formalin (10%) and then
embedded in paraffin. Sections were prepared and stained with
hematoxylin and eosin by the Division of Comparative Medicine core
facility at WUSM. Histological sections were reviewed by an independent
veterinary pathologist.

Statistics
Nonparametric tests were used to compare non-Gaussian data. All
quantitative data are fully displayed in graphs, as they are represented
either with box and whisker plots (line shows the median value, box
shows 25th to 75th percentiles, and whiskers show minimum and
maximum values) or with symbols indicating each value. Comparisons
of two groups were made with the Mann-Whitney U test, and
comparisons of multiple groups used the Kruskal-Wallis test.
Survival curves were compared using the log-rank Mantel-Cox test.
A P value of <0.05 was considered statistically significant.
As these studies were performed to generate preliminary data and
demonstrate feasibility, power calculations could not be performed
in advance; the number of experiments to be performed was determined on the basis of the number of experiments required in prior
reports to demonstrate differences between groups of animals (22, 25).
End points of all experiments were determined in advance of
performing the experiment. All results of all experiments that were
technically interpretable were included. No outliers from any experiment were excluded. The number of animals and replicates for
each experiment is provided in the figure or legend.
SUPPLEMENTARY MATERIALS

Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/5/8/eaax3387/DC1
Fig. S1. No increase in mature AMs following the subcutaneous administration of rGM-CSF
(20 ng) to LPL−/− neonatal pups on DOB, PND1, and PND2.
Fig. S2. No disruption of alveolarization observed after intranasal neonatal rGM-CSF therapy.
Fig. S3. Increased SP-D in LPL−/− PND3 neonatal pups.
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